– Niels Bohr Institute - University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Niels Bohr Institute > Staff

Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells

Publication: Research - peer-reviewJournal article

Documents

  • srep22478

    Final published version, 1 MB, PDF-document

Murillo Longo Martins, Rosanna Ignazzi, Juergen Eckert, Benjamin Watts, Ramon Kaneno, Willian F Zambuzzi, Luke Daemen, Margarida J Saeki, Heloisa N Bordallo

The most common cancer treatments currently available are radio- and chemo-therapy. These therapies have, however, drawbacks, such as, the reduction in quality of life and the low efficiency of radiotherapy in cases of multiple metastases. To lessen these effects, we have encapsulated an anti-cancer drug into a biocompatible matrix. In-vitro assays indicate that this bio-nanocomposite is able to interact and cause morphological changes in cancer cells. Meanwhile, no alterations were observed in monocytes and fibroblasts, indicating that this system might carry the drug in living organisms with reduced clearance rate and toxicity. X-rays and neutrons were used to investigate the carrier structure, as well as to assess the drug mobility within the bio-nanocomposite. From these unique data we show that partial mobility restriction of active groups of the drug molecule suggests why this carrier design is potentially safer to healthy cells.

Original languageEnglish
Article number22478
JournalScientific Reports
Volume6
ISSN2045-2322
DOIs
StatePublished - 2016

Number of downloads are based on statistics from Google Scholar and www.ku.dk


No data available

ID: 160795942